The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products; Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay
Authors:
Open Access
- 1 January 2021
- journal article
- research article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 27
Abstract
The FVIII activity in patients treated with several extended half-life FVIII (EHL-FVIII) agents different when various activated partial thromboplastin time (APTT) reagents were used. The present study examined the difference in clot waveform analysis (CWA) findings and FVIII activity when various APTT reagents and CWA were used. The CWA including FVIII activity was measured using 12 APTT reagents, and the FIX activation based on a small amount of tissue factor assay (sTF/FIX) were examined in reference plasma (RP), EHL-FVIII (Jivi®) and Kovaltry®. The 3 APTT reagents were associated with high variation in the peak time and height in the CWA when analyzing low concentrations of FVIII. The peak time and height could not be measured with one APTT reagent, and there were marked differences in the CWA findings between Jivi® and Kovaltry® among APTT reagents. Several APTT reagents showed a markedly lower FVIII activity with Jivi® than with Kovaltry®. In the FVIII assay, the peak time measured with sTF/FIX did not differ markedly between Jivi® and Kovaltry®; however, the FVIII activity in Jivi® (as measured by the peak height) tended to be higher than in Kovaltry®. The CWA findings for monitoring Jivi® varied for monitoring Jivi® depending on the APTT reagents used, and sTF/FIX assay may be able to measure the EHL-FVIII.Keywords
Funding Information
- Japanese Ministry of Health, Labor and Welfare
This publication has 21 references indexed in Scilit:
- A computer‐based model to assess costs associated with the use of factor VIII and factor IX one‐stage and chromogenic activity assaysJournal of Thrombosis and Haemostasis, 2016
- Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulatorsHaemophilia, 2015
- Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94‐9027) for haemophilia AHaemophilia, 2014
- Thrombin Generation Testing for Monitoring Hemophilia Treatment: A Clinical PerspectiveSeminars in Thrombosis and Hemostasis, 2010
- Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatmentBlood, 2010
- Longer‐acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issueHaemophilia, 2010
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Frequency of Abnormal Biphasic aPTT Clot Waveforms in Patients with Underlying Disorders Associated with Disseminated Intravascular CoagulationClinical and Applied Thrombosis/Hemostasis, 2006
- Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysisSeminars in Hematology, 2004
- Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca++-dependent complex of C-reactive protein with very-low–density lipoprotein and is a novel marker of impending disseminated intravascular coagulationBlood, 2002